Showing results (1-10 of 81) with videos related to
Sort By:
Pageof 9
European Journal of Clinical Pharmacology|January 1, 1995
References used in a drug information centreA Llerena, B Ohman, G AlvánClinical Pharmacology and Therapeutics|July 1, 1988
Debrisoquin oxidation polymorphism in a Spanish populationJ Benítez, A LLerena, J CobaledaEuropean Journal of Drug Metabolism and Pharmacokinetics|April 1, 1996
Interethnic differences in drug metabolism: influence of genetic and environmental factors on debrisoquine hydroxylation phenotypeA Llerena, J Cobaleda, C Martínez, et al.Therapeutic Drug Monitoring|June 1, 1992
Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizersA Llerena, M L Dahl, B Ekqvist, et al.Pharmacology & Toxicology|July 1, 1993
Reproducibility over time of mephenytoin and debrisoquine hydroxylation phenotypesA Llerena, M J Valdivielso, J Benítez, et al.Revista De Enfermeria (Barcelona, Spain)|August 2, 2002
[Optimizing pharmacologic therapy for the elderly]M J Norberto, M Martínez, M C Cáceres, et al.Neurologia|May 16, 2015
Pharmacogenetics of adverse reactions to antiepileptic drugsI Fricke-Galindo, H Jung-Cook, A LLerena, et al.Actas Espanolas De Psiquiatria|October 17, 2001
[Prevalence of polydipsia and water intoxication in psychiatric inpatients]A Llerena, A De la Rubia Martínez, E M Peñas-LledóJournal of Chromatography. B, Biomedical Sciences and Applications|June 8, 2001
Determination of clozapine and its N-desmethyl metabolite by high-performance liquid chromatography with ultraviolet detectionA Llerena, R Berecz, M J Norberto, et al.British Journal of Clinical Pharmacology|January 1, 1994
Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphismsM L Dahl, A Llerena, U Bondesson, et al.Pageof 9